Chiu, Hsien TsungHsien TsungChiuLI-JIUAN SHENYEE-CHUN CHENLin, Jung HsinJung HsinLinCHI-CHUAN WANG2020-07-152020-07-152018-10-010264410Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/510050© 2018 Elsevier Ltd Objectives: The immunomodulatory effects of statins may reduce the immune response induced by influenza vaccines. However, evidence regarding the effect of statin use on the effectiveness of seasonal influenza vaccines against medically attended acute respiratory illness (MAARI) in the elderly remains scarce. Methods: We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. Elderly adults aged ≧ 66 years who were vaccinated with seasonal influenza vaccines during the 2007–2008 to 2012–2013 influenza seasons were enrolled for this analysis. We compared the risk of MAARI between statin and non-statin users. Propensity score matching and conditional logistic regression models were used to analyze the data. Results: A total of 440,180 elderly were included in this study. In general, the risk of MAARI was higher in statin users than non-statin users (odds ratio [OR]: 1.03, 95% confidence interval [CI]: 1.02–1.05). Statin exposure after vaccination was associated with a higher risk of MAARI (OR: 1.05, 95% CI: 1.02–1.07). Among different statin agents, simvastatin and lovastatin use was associated with a significant increase in the risk of MAARI (ORsimvastatin: 1.14, 95% CI: 1.10–1.18; ORlovastatin: 1.18, 95% CI: 1.12–1.25). Conclusions: Statin exposure, especially simvastatin and lovastatin, was associated with a higher risk of MAARI in the seasonal influenza vaccinated elderly. Future studies exploring the differences between individual statins and mechanisms of their immunomodulatory effects are necessary.animationElderly | Medically attended acute respiratory illness | Seasonal influenza vaccine | Statin | Vaccine effectivenessElderly; Medically attended acute respiratory illness; Seasonal influenza vaccine; Statin; Vaccine effectiveness[SDGs]SDG3influenza vaccine; mevinolin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; influenza vaccine; mevinolin; simvastatin; acute respiratory tract disease; aged; Article; cohort analysis; controlled study; drug potency; drug use; female; human; influenza vaccination; major clinical study; male; medically attended acute respiratory illness; priority journal; retrospective study; risk assessment; risk factor; seasonal influenza; very elderly; immunology; influenza; respiratory tract infection; statistical model; Aged; Aged, 80 and over; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza Vaccines; Influenza, Human; Logistic Models; Lovastatin; Male; Respiratory Tract Infections; Retrospective Studies; Simvastatinjournal article10.1016/j.vaccine.2018.08.067301742392-s2.0-85052743428WOS:000447096400013https://api.elsevier.com/content/abstract/scopus_id/85052743428